When Is Tysabri PML Risk Evaluated? A Chronology of Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Risk Awareness

If you or a loved one is taking Tysabri, understanding when PML risk is evaluated can help you stay informed about monitoring schedules and warning signs. The medical community has long recognized the importance of structured risk assessment for patients on immunosuppressive therapies, and this page outlines the typical timeline and documentation of PML screening.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn's disease (CD) in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus (JCV). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is an infection of the brain's white matter that typically occurs only in immunocompromised individuals. In Tysabri-treated patients, the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML can include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking, memory, and personality, and, in later stages, seizures and coma. Diagnosis is confirmed through brain MRI showing characteristic lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). Early recognition is critical because the disease can progress rapidly.

Mechanism of Action and Risk Factors

The mechanistic link between Tysabri and PML involves the drug's mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration from the bloodstream into tissues, including the central nervous system. This reduces inflammation in MS but also impairs immune surveillance in the brain. Under normal conditions, JCV is kept in check by a competent immune system. When Tysabri blocks immune cell trafficking, latent JCV can reactivate and cause lytic infection of oligodendrocytes, the cells that produce myelin. This leads to demyelination and the clinical syndrome of PML. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML compared to those who are negative. The risk increases with cumulative exposure, and patients who have previously taken immunosuppressants (such as mitoxantrone, cyclophosphamide, or azathioprine) are at even greater risk. These factors should be weighed against the expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Timeline of Exposure and Legal Implications

The timeline between Tysabri exposure and PML onset can vary. In clinical trials, PML occurred in three patients: two with MS who had received Tysabri for a median of 120 weeks (approximately 2.3 years) in addition to interferon beta-1a, and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data have shown that PML can occur as early as a few months after starting therapy, but the risk increases significantly after two years of continuous treatment. Because of this risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers, patients, and pharmacies to enroll and adhere to specific monitoring protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The FDA boxed warning clearly states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, withholding the drug immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients and their families have alleged that these warnings were not sufficiently communicated or that the risks were downplayed relative to the benefits. In Michigan, as in other states, patients who develop PML after Tysabri treatment may pursue legal claims against the manufacturer, Biogen, for failure to warn, negligence, or product liability. Settlement considerations for affected patients often include the severity of disability, medical expenses, lost earning capacity, and pain and suffering. The timeline between exposure and documented harm is a critical factor in these cases, as it can establish causation and the point at which the manufacturer should have been aware of the risk.

Legal Recourse for Michigan Patients

In summary, Tysabri is an effective therapy for MS and Crohn's disease but carries a significant risk of PML, a devastating brain infection. The risk is highest in patients with anti-JCV antibodies, those on long-term therapy, and those with prior immunosuppressant use. Early diagnosis and prompt discontinuation of Tysabri are essential to improve outcomes. For patients in Michigan who have developed PML after Tysabri treatment, legal options may include seeking compensation through settlements or litigation, based on the adequacy of warnings and the specific circumstances of their case.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

The three main risk factors are: presence of anti-JCV antibodies, treatment duration longer than two years, and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can Michigan patients file a lawsuit if they develop PML from Tysabri?

Yes, patients in Michigan who develop PML after Tysabri treatment may pursue legal claims against the manufacturer for failure to warn, negligence, or product liability. Settlements may cover medical expenses, lost income, and pain and suffering.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.